Bioelectrical Impedance Phase Angle in Predicting Treatment Outcome in Patients With Extensive Stage Small Cell Lung Cancer Receiving First-Line Chemotherapy
Stopped early · Not applicable
Conditions studied: Extensive Stage Small Cell Lung Cancer
In brief
This clinical trial studies bioelectrical impedance phase angle in predicting treatment outcome in patients with extensive stage small cell lung cancer receiving first-line chemotherapy. Diagnostic procedures, such as bioelectrical impedance analysis, may help predict a patient's response to treatment for small cell lung cancer.
Key facts
- Study ID
- NCT02011087
- Run by
- Wake Forest University Health Sciences
- People needed
- 1
- Starts
- 2014-02-01
- Expected to finish
- 2016-09-01
- Last updated by the study team
- 2018-07-05
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- A primary histopathological and/or cytopathological diagnosis of small cell lung cancer (SCLC)
- Diagnosis of extensive stage disease (extensive stage [ES]-SCLC), with stage established by computed tomography (CT), magnetic resonance imaging (MRI), or positron emission tomography (PET) scan
- Scheduled to receive front-line platinum-based chemotherapy with carboplatin or cisplatin plus etoposide
- Ability to understand and the willingness to sign an institutional review board (IRB)-approved informed consent document
You may not qualify if…
- No recent chemotherapy or surgery, as defined as in the last 6 months
- Presence of a pacemaker or defibrillator
- Patients with major chronic disease known to adversely affect PA, including human immunodeficiency virus (HIV)/acquired immune deficiency syndrome (AIDS), congestive heart failure, tuberculosis
- Patients with body mass index (BMI) greater than 34 or less than 16
- Any condition or abnormality which may, in the opinion of the investigator, compromise the safety of patients
- Unable or unwilling to follow protocol requirements
- Pregnant women are excluded from participation due to inability to participate in required chemotherapy regimen
Where it is running
- Comprehensive Cancer Center of Wake Forest University — Winston-Salem, North Carolina, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.